American Journal of Tropical Medicine and Hygiene · 2010 · 43 citations · 25 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyClinical PharmacologyInfectious Disease PharmacotherapyLiposomal FormulationsTreatmentAdverse Drug EventsAntileishmanial TreatmentLips LesionsTreatment Of LeishmaniasisVisceral Leishmaniasis
We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for the treatment of visceral leishmaniasis. The treatment success rates for the intention-to-treat, per protocol, and intention-to-treat worse-case scenario analyses were 98.8%, 99.6%, and 81.3%, respectively. Nearly one-half of patients experienced mild adverse events, but only 1% developed serious but non-life-threatening lips swelling. The lost to follow-up rate was 17.5%. Our findings indicate that the 20 mg/kg body weight treatment dosage is effective and safe under routine program conditions. Given that the exorbitant cost of liposomal amphotericin B is a barrier to its widespread use, we recommend further study to monitor and evaluate a lowered dosage and a shorter treatment course.
25
Oral Miltefosine for Indian Visceral Leishmaniasis
Shyam Sundar, T. K. Jha, C.P. Thakur et al. · New England Journal of Medicine · 2002 · 774 citations · Full text
Injectable Paromomycin for Visceral Leishmaniasis in India
Shyam Sundar, T. K. Jha, Chandreshwar Prasad Thakur et al. · New England Journal of Medicine · 2007 · 464 citations
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Shyam Sundar, Jaya Chakravarty, Dipti Agarwal et al. · New England Journal of Medicine · 2010 · 427 citations · Full text
Rosalía Lira, Shyam Sundar, Anand Makharia et al. · The Journal of Infectious Diseases · 1999 · 367 citations · Full text